WO2021037291A3 - 具有多功能活性的融合多肽及其应用 - Google Patents

具有多功能活性的融合多肽及其应用 Download PDF

Info

Publication number
WO2021037291A3
WO2021037291A3 PCT/CN2020/123553 CN2020123553W WO2021037291A3 WO 2021037291 A3 WO2021037291 A3 WO 2021037291A3 CN 2020123553 W CN2020123553 W CN 2020123553W WO 2021037291 A3 WO2021037291 A3 WO 2021037291A3
Authority
WO
WIPO (PCT)
Prior art keywords
gly
arg
fusion polypeptide
ala
multifunctional activities
Prior art date
Application number
PCT/CN2020/123553
Other languages
English (en)
French (fr)
Other versions
WO2021037291A2 (zh
Inventor
康志安
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to US17/635,962 priority Critical patent/US20220332796A1/en
Priority to CA3149606A priority patent/CA3149606A1/en
Priority to GB2201002.9A priority patent/GB2600593A/en
Priority to AU2020339062A priority patent/AU2020339062A1/en
Publication of WO2021037291A2 publication Critical patent/WO2021037291A2/zh
Publication of WO2021037291A3 publication Critical patent/WO2021037291A3/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了具有多功能活性的融合多肽，该融合多肽的氨基酸序列为：Pro-Arg-Cys-X-Y-Gly-Glu-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp,其中X是Trp或Tyr,Y是Arg或Cys。本发明的融合多肽可用于治疗各种纤维化疾病及肺部组织病变。
PCT/CN2020/123553 2019-08-27 2020-10-26 具有多功能活性的融合多肽及其应用 WO2021037291A2 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/635,962 US20220332796A1 (en) 2019-08-27 2020-10-26 Fused polypeptide with multifunctional activities and use thereof
CA3149606A CA3149606A1 (en) 2019-08-27 2020-10-26 Fused polypeptide with multifunctional activities and use thereof
GB2201002.9A GB2600593A (en) 2019-08-27 2020-10-26 Fused polypeptide with multifunctional activities and use thereof
AU2020339062A AU2020339062A1 (en) 2019-08-27 2020-10-26 Fusion polypeptide having multifunctional activities and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910796360.X 2019-08-27
CN201910796360.XA CN110372800B (zh) 2019-08-27 2019-08-27 具有多功能活性的融合多肽及其应用

Publications (2)

Publication Number Publication Date
WO2021037291A2 WO2021037291A2 (zh) 2021-03-04
WO2021037291A3 true WO2021037291A3 (zh) 2021-04-22

Family

ID=68260821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/123553 WO2021037291A2 (zh) 2019-08-27 2020-10-26 具有多功能活性的融合多肽及其应用

Country Status (6)

Country Link
US (1) US20220332796A1 (zh)
CN (1) CN110372800B (zh)
AU (1) AU2020339062A1 (zh)
CA (1) CA3149606A1 (zh)
GB (1) GB2600593A (zh)
WO (1) WO2021037291A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110372800B (zh) * 2019-08-27 2022-06-07 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
CN104045718A (zh) * 2014-07-08 2014-09-17 南京安吉生物科技有限公司 多功能融合多肽及其制备方法和应用
WO2015095628A1 (en) * 2013-12-19 2015-06-25 Consejo Nacional De Investigaciones Cientificas Y Tecnicas Isoform of the tgf-beta receptor ii
CN105713095A (zh) * 2016-03-14 2016-06-29 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
CN109879969A (zh) * 2017-12-06 2019-06-14 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN110372800A (zh) * 2019-08-27 2019-10-25 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384830B (zh) * 2017-08-09 2021-12-03 成都惠泰生物医药有限公司 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
WO2015095628A1 (en) * 2013-12-19 2015-06-25 Consejo Nacional De Investigaciones Cientificas Y Tecnicas Isoform of the tgf-beta receptor ii
CN104045718A (zh) * 2014-07-08 2014-09-17 南京安吉生物科技有限公司 多功能融合多肽及其制备方法和应用
CN105713095A (zh) * 2016-03-14 2016-06-29 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
CN109879969A (zh) * 2017-12-06 2019-06-14 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN110372800A (zh) * 2019-08-27 2019-10-25 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Also Published As

Publication number Publication date
CN110372800B (zh) 2022-06-07
CN110372800A (zh) 2019-10-25
US20220332796A1 (en) 2022-10-20
WO2021037291A2 (zh) 2021-03-04
AU2020339062A1 (en) 2022-03-10
GB2600593A (en) 2022-05-04
GB202201002D0 (en) 2022-03-09
GB2600593A9 (en) 2022-06-15
CA3149606A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EP3935156A4 (en) CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE
WO2021127487A3 (en) Novel il2 agonists and methods of use thereof
WO2009067639A3 (en) Variants of c-type natriuretic peptide
MY193457A (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2021037290A3 (zh) 一种融合多肽及其应用
WO2021037291A3 (zh) 具有多功能活性的融合多肽及其应用
WO2004050171A3 (en) Devices and methods for selective orientation of electrosurgical devices
AU2003264514A1 (en) Wt1 substitution peptides
EP3798725A4 (en) CONVERTIBLE BALL JOINT ASSEMBLY WITH TWO DEGREES OF FREEDOM AND THREE DEG OF FREEDOM
EP3935155A4 (en) CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
WO2010126156A3 (en) Alkaline protease variants
WO2021037289A3 (zh) 一种重组融合多肽及其应用
WO2021037292A3 (zh) 一种多肽及其应用
TWD206473S (zh) 無線聽診器
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
EP4295901A3 (en) Fish protein hydrolysate powder and a composition comprising said powder for use as a medicament
EP3980067A4 (en) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP3814488A4 (en) RNA-GUIDED EFFECTIVE PROTEINS AND METHODS OF USE THEREOF
WO2000037487A8 (de) INHIBITOREN DES INTEGRINS αvβ¿6?
Harken A review of the activities of the thoracic center for the III and IV hospital groups, 160th General Hospital European Theater of Operations, June 10, 1944 to Jan. 1, 1945
WO2002065943A3 (en) Ocular tear growth factor-like protein
EP4003391A4 (en) PEPTIDES AND THEIR METHODS OF USE
WO2004065406A3 (en) Rantes-derived peptides with anti-hiv activity
WO2021207636A3 (en) Compositions and methods for the treatment of protein aggregation disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20858748

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202201002

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20201026

ENP Entry into the national phase

Ref document number: 3149606

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020339062

Country of ref document: AU

Date of ref document: 20201026

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20858748

Country of ref document: EP

Kind code of ref document: A2